SV2011003973A - Estimuladores de la sgc o activadores de la sgc en combinacion con inhibidores de la pde5 para el tratamiento de la disfuncion erectil - Google Patents
Estimuladores de la sgc o activadores de la sgc en combinacion con inhibidores de la pde5 para el tratamiento de la disfuncion erectilInfo
- Publication number
- SV2011003973A SV2011003973A SV2011003973A SV2011003973A SV2011003973A SV 2011003973 A SV2011003973 A SV 2011003973A SV 2011003973 A SV2011003973 A SV 2011003973A SV 2011003973 A SV2011003973 A SV 2011003973A SV 2011003973 A SV2011003973 A SV 2011003973A
- Authority
- SV
- El Salvador
- Prior art keywords
- sgc
- treatment
- combination
- activators
- erectile dysfunction
- Prior art date
Links
- 239000012190 activator Substances 0.000 title abstract 3
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 title abstract 3
- 208000010228 Erectile Dysfunction Diseases 0.000 title abstract 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 201000001881 impotence Diseases 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
- 101150098694 PDE5A gene Proteins 0.000 abstract 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A GUANILATO CICLASA SOLUBLES (SGC) Y A FOSFODIESTERASAS (PDE) Y A LA FARMACOLOGÍA DE LOS ESTIMULADORES DE SGC, ACTIVADORES DE SGC E INHIBIDORES DE PDE. MÁS PARTICULARMENTE, LA INVENCIÓN SE REFIERE AL USO DE ESTIMULADORES DE SGC Y A ACTIVADORES DE SGC EN COMBINACIÓN CON INHIBIDORES DE LA PDE5 PARA LA PREPARACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO DE LA DISFUNCIÓN ERÉCTIL MASCULINA (DEM), EN PARTICULAR PARA EL TRATAMIENTO DE LA DEM DE PACIENTES DIFÍCILES DE TRATAR Y DE PACIENTES NO RESPONDEDORES, O NO COMPLETAMENTE RESPONDEDORES, A LOS INHIBIDORES DE LA PDE5
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09000619 | 2009-01-17 | ||
EP09002177 | 2009-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2011003973A true SV2011003973A (es) | 2011-12-06 |
Family
ID=42153923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2011003973A SV2011003973A (es) | 2009-01-17 | 2011-07-14 | Estimuladores de la sgc o activadores de la sgc en combinacion con inhibidores de la pde5 para el tratamiento de la disfuncion erectil |
Country Status (20)
Country | Link |
---|---|
US (2) | US20120022028A1 (es) |
EP (1) | EP2387404B1 (es) |
JP (1) | JP5780430B2 (es) |
KR (1) | KR20110117655A (es) |
CN (1) | CN102316870A (es) |
AU (1) | AU2010205931A1 (es) |
BR (1) | BRPI1006869A2 (es) |
CA (1) | CA2749730C (es) |
CL (1) | CL2011001712A1 (es) |
EA (1) | EA201170942A1 (es) |
ES (1) | ES2493718T3 (es) |
IL (1) | IL213857A0 (es) |
MA (1) | MA32967B1 (es) |
MX (1) | MX2011007515A (es) |
SG (1) | SG172841A1 (es) |
SV (1) | SV2011003973A (es) |
TN (1) | TN2011000349A1 (es) |
TW (1) | TW201036971A (es) |
WO (1) | WO2010081647A2 (es) |
ZA (1) | ZA201105085B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011095553A1 (en) * | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
CA2955143C (en) | 2010-05-26 | 2020-02-11 | Claudia Hirth-Dietrich | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc). |
WO2011161099A1 (de) * | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
EP2766360B1 (en) | 2011-08-12 | 2017-07-12 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
KR101960100B1 (ko) * | 2011-12-08 | 2019-03-19 | 에스케이케미칼 주식회사 | 미로데나필 또는 이의 약학적으로 허용 가능한 염을 함유하는 구강 투여용 필름 |
RS59394B1 (sr) * | 2012-09-07 | 2019-11-29 | Boehringer Ingelheim Int | Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklaze |
EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
WO2016014463A1 (en) | 2014-07-22 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
CA3001728A1 (en) | 2015-11-16 | 2017-05-26 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
WO2018215433A1 (en) | 2017-05-22 | 2018-11-29 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
CN113166157A (zh) | 2018-11-28 | 2021-07-23 | 托帕杜制药公司 | 新型双作用模式可溶性鸟苷酸环化酶活化剂和磷酸二酯酶抑制剂及其用途 |
CN110305837A (zh) * | 2019-06-05 | 2019-10-08 | 西北师范大学 | 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用 |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB371800A (en) | 1929-10-21 | 1932-04-28 | Willem Zaadnoordijk | A process of filtering gases and fogs |
GB369003A (en) | 1931-03-25 | 1932-03-17 | Richard Henry Sansome | Improvements in fire extinguishing fluids |
HU228111B1 (en) * | 1998-07-08 | 2012-11-28 | Sanofi Aventis Deutschland | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
US20100144864A1 (en) * | 2007-04-05 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
MX2009011387A (es) * | 2007-05-12 | 2009-11-09 | Bayer Schering Pharma Ag | Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos. |
-
2010
- 2010-01-07 SG SG2011048840A patent/SG172841A1/en unknown
- 2010-01-07 AU AU2010205931A patent/AU2010205931A1/en not_active Abandoned
- 2010-01-07 CA CA2749730A patent/CA2749730C/en not_active Expired - Fee Related
- 2010-01-07 WO PCT/EP2010/000029 patent/WO2010081647A2/en active Application Filing
- 2010-01-07 KR KR1020117016559A patent/KR20110117655A/ko not_active Application Discontinuation
- 2010-01-07 MX MX2011007515A patent/MX2011007515A/es not_active Application Discontinuation
- 2010-01-07 EA EA201170942A patent/EA201170942A1/ru unknown
- 2010-01-07 CN CN2010800047775A patent/CN102316870A/zh active Pending
- 2010-01-07 US US13/144,929 patent/US20120022028A1/en not_active Abandoned
- 2010-01-07 EP EP10700938.3A patent/EP2387404B1/en active Active
- 2010-01-07 BR BRPI1006869A patent/BRPI1006869A2/pt not_active Application Discontinuation
- 2010-01-07 JP JP2011545666A patent/JP5780430B2/ja not_active Expired - Fee Related
- 2010-01-07 ES ES10700938.3T patent/ES2493718T3/es active Active
- 2010-01-07 MA MA34016A patent/MA32967B1/fr unknown
- 2010-01-15 TW TW099101001A patent/TW201036971A/zh unknown
-
2011
- 2011-06-30 IL IL213857A patent/IL213857A0/en unknown
- 2011-07-11 ZA ZA2011/05085A patent/ZA201105085B/en unknown
- 2011-07-14 CL CL2011001712A patent/CL2011001712A1/es unknown
- 2011-07-14 TN TN2011000349A patent/TN2011000349A1/fr unknown
- 2011-07-14 SV SV2011003973A patent/SV2011003973A/es unknown
-
2014
- 2014-03-18 US US14/217,664 patent/US20140288079A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2011007515A (es) | 2011-08-12 |
CN102316870A (zh) | 2012-01-11 |
IL213857A0 (en) | 2011-07-31 |
TN2011000349A1 (en) | 2013-03-27 |
AU2010205931A1 (en) | 2011-07-28 |
ZA201105085B (en) | 2012-09-26 |
JP2012515176A (ja) | 2012-07-05 |
WO2010081647A3 (en) | 2010-10-21 |
ES2493718T3 (es) | 2014-09-12 |
CA2749730A1 (en) | 2010-07-22 |
CL2011001712A1 (es) | 2012-04-09 |
KR20110117655A (ko) | 2011-10-27 |
WO2010081647A2 (en) | 2010-07-22 |
MA32967B1 (fr) | 2012-01-02 |
JP5780430B2 (ja) | 2015-09-16 |
CA2749730C (en) | 2017-02-14 |
BRPI1006869A2 (pt) | 2016-03-15 |
EP2387404B1 (en) | 2014-06-25 |
EP2387404A2 (en) | 2011-11-23 |
SG172841A1 (en) | 2011-08-29 |
US20140288079A1 (en) | 2014-09-25 |
TW201036971A (en) | 2010-10-16 |
US20120022028A1 (en) | 2012-01-26 |
EA201170942A1 (ru) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2011003973A (es) | Estimuladores de la sgc o activadores de la sgc en combinacion con inhibidores de la pde5 para el tratamiento de la disfuncion erectil | |
CR20120408A (es) | ESTIMULADORES DE LA sGC O ACITVADORES DE LA sGC SOLOS Y EN COMBINACIÓN CON INHIBIDORES DE LA PDE5 PARA EL TRATAMIENTO DE LA FIBROSIS QUÍSTICA | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2011003082A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. | |
GT201300137A (es) | Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak | |
CL2012000248A1 (es) | Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina. | |
GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
GT201200243A (es) | Derivados de pirazol como inhibidores de jak | |
UY32728A (es) | Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia | |
CR20110596A (es) | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas | |
DOP2011000260A (es) | Pirimidinas fusionadas | |
CL2011002548A1 (es) | Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica. | |
CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
PA8846201A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
CL2012002954A1 (es) | Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros. | |
CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
SV2010003773A (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
CL2013000434A1 (es) | Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia. | |
DOP2013000090A (es) | HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-{2,4- BIS(TRIFUOROMETIL)-5,8-DI-HIDROPIRIDO{3,4-d} PIRIMIDIN-7 (6H)-IL}-4-OXOBUTIL}-5,5-DIFLUORO-PIRIDIN-2-ONA | |
CL2009000264A1 (es) | Uso de una combinacion farmaceutica que comprende una sal de bis-tiazolio o uno de sus precursores y artemisina o uno de sus derivados, para el tratamiento y/o prevencion de la malaria severa; uso de la composicion farmaceutica y del kit farmaceutico que la comprenden. | |
CL2009001112A1 (es) | Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. |